Cardiotoxicity and cardiac monitoring following the use of radiotheranostics agents including 177Lu-PSMA for prostate cancer and 177Lu-DOTATATE for neuroendocrine tumors - Jafari, E; Amini, AL; Ahmadzadehfar, H (Nuklearmedizin-NuclearMedicine, 2021)